. . . . . . . . . . . . . . "a(CHEBI:cisplatin) -| cat(p(HGNC:GCLM))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "CDDP-resistance was more effectively ameliorated when GCLM rather than GCLC was inhibited. GCLM is a potentially more effective pharmacologic target for ameliorating CDDP-resistance in non-small cell lung cancer than GCLC." . . "Selventa" . . . . "2014-07-03T14:30:17.314+02:00"^^ . . .